According to Mike Capone, Medidata's chief operating officer, the partnership will allow life sciences companies and contract research organizations (CRO) to combine real world evidence (RWE) data from electronic medical records (EMRs) and health claims with “information traditionally collected in clinical trials.”
“Our partnership with SHYFT is focused on providing life sciences companies and their CRO partners with the ability to analyze real world evidence data to improve study design, feasibility, and site selection,” Capone told Outsourcing-Pharma.com.
The partnership will combine Medidata’s clinical technology platform and SHYFT’s intelligent analytics.
The offering will also help companies more efficiently recruit patients for clinical trials by identifying specific patient populations – “down to very specific indications,” Capone explained.
Capone said the next step will be identifying customers for the offering.
“Regulators, payers and prescribers are increasingly interested in better understanding the impact of new drugs in a real world setting,” he added.
“As life sciences companies focus on more complex and targeted programs across a range of therapeutic areas, there is a growing need for broader information on real world effectiveness, and a need to bring those insights into the clinical development process earlier,” he added.